Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

Inclusion Criteria: * Patients must have had histologic verification of osteosarcoma at original diagnosis * Patients must have measurable disease, documented by clinical, radiographic, or histologic criteria, and have relapsed or become refractory to conventional therapy * Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients \> 16 years of age and Lansky for patients =\< 16 years of age * Patients must have a life expectancy of \>= 8 weeks * Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study * Myelosuppressive chemotherapy: must not have received within 2 weeks of entry onto this study (6 weeks if prior nitrosourea) * Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy with a biologic agent * Bisphosphonates: at least 4 weeks since the completion of therapy with a bisphosphonate * Monoclonal antibodies: at least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody * Radiation therapy (RT): \>= 2 weeks (wks) for local palliative RT (small port); \>= 6 months must have elapsed if prior craniospinal RT or if \>= 50% radiation of pelvis; \>= 6 weeks must have elapsed if other substantial bone marrow (BM) radiation * Peripheral absolute neutrophil count (ANC) \>= 1000/uL * Platelet count \>= 75,000/uL (transfusion independent) * Hemoglobin \>= 8.0 g/dL (may receive red blood cell \[RBC\] transfusions) * Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2 or * A serum creatinine based on age/gender as follows: (threshold creatinine values were derived from the Schwartz formula for estimating GFR) * Age (12 to \< 13 years) - serum creatinine of 1.2 mg/dL * Age (13 to \< 16 years) - serum creatinine of 1.5 mg/dL (male) and 1.4 mg/dL (female) * Age (\>= 16 years) - serum creatinine of 1.7 mg/dL (male) and 1.4 mg/dL (female) * Bilirubin (sum of conjugate + unconjugated) =\< 1.5 x upper limit of normal (ULN) for age * Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 110 units per liter (U/L); for the purpose of this study, the ULN for SGPT is 45 U/L * Serum albumin \> 2 g/dL * Shortening fraction of \>= 27% by echocardiogram * Ejection fraction of \>= 50% by radionuclide angiogram * All patients and/or their parents or legal guardians must sign a written informed consent * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met Exclusion Criteria: * Patients with congenital prolonged QT syndrome * Patients with a baseline QT/corrected QT (QTc) interval \>= 501 msec * Patients who are receiving drugs that prolong the QTc are not eligible * Patients who have previously received eribulin, halichondrin B, or analogues of halichondrin B * Patients who have grade \>= 2 peripheral neuropathy * Patients who are receiving other cancer directed therapy at the time of enrollment * Patients who have had major surgery within 3 weeks prior to enrollment are not eligible; procedures such as placement of a central vascular catheter, or limited tumor biopsy, are not considered major surgery * Pregnancy and breast feeding * Female patients who are pregnant are ineligible * Lactating females are not eligible unless they have agreed not to breastfeed their infants * Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained * Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation